Cidara Therapeutics, Inc. announced the completion of patient enrollment in the RADIANT trial, a Phase 2 randomized trial evaluating the safety, tolerability and efficacy of two topical treatment regimens of the novel echinocandin antifungal, CD101, in women with moderate to severe acute vulvovaginal candidiasis (VVC). CD101 topical is the first and only agent in the echinocandin class being studied for the treatment and prevention of VVC. RADIANT is a Phase 2, multicenter, randomized, open-label, active-controlled, dose-ranging trial designed to evaluate the safety and tolerability of CD101 topical in women with moderate to severe acute episodes of VVC. The trial includes women with and without a history of recurrent VVC (RVVC). The 125 trial participants were randomized into three treatment cohorts. The first cohort involved the treatment of 50 patients with CD101 Gel while a second cohort of 50 patients received CD101 Ointment. The third cohort comprised 25 patients who were treated with oral fluconazole. The primary endpoint for the RADIANT trial is the safety and tolerability of two doses of CD101 Gel versus a single dose of CD101 Ointment in patients with an episode of moderate to severe acute VVC. Secondary endpoints include efficacy in women with acute VVC treated with CD101. The trial was conducted at clinical trial centers across the United States. Cidara expects to report topline data for RADIANT in the first quarter of 2017.